{"id":742134,"date":"2011-03-22T02:00:00","date_gmt":"2011-03-22T02:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-sanofi-aventis-to-maintain-separate-businesses-in-animal-health\/"},"modified":"2026-08-10T13:01:18","modified_gmt":"2026-08-10T17:01:18","slug":"merck-and-sanofi-aventis-to-maintain-separate-businesses-in-animal-health","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-sanofi-aventis-to-maintain-separate-businesses-in-animal-health\/","title":{"rendered":"Merck and sanofi-aventis to Maintain Separate Businesses in Animal Health"},"content":{"rendered":"<p>WHITEHOUSE STATION, N.J. &amp; PARIS&#8211;(BUSINESS WIRE)&#8211;Merck (NYSE: MRK) and sanofi-aventis (EURONEXT: SAN and NYSE: SNY)        announced today the mutual termination of their agreement to form a new        animal health joint venture by combining Merial, the animal health        business of sanofi-aventis, with Intervet\/Schering-Plough, Merck&#8217;s        animal health unit. As a result, each party will keep its current,        separate animal health assets and businesses.     <\/p>\n<p>       Since the initial announcement about the intended combination on March        9, 2010, both companies have worked diligently to create the proposed        animal health joint venture, including submitting requests for the        required antitrust reviews. The companies are discontinuing their        agreement primarily because of the increasing complexity of implementing        the proposed transaction, both in terms of the nature and extent of the        anticipated divestitures and the length of time necessary for the        worldwide regulatory review process. Merck and sanofi-aventis mutually        determined that ending their plan is in the best interests of both        companies and their respective shareholders, as well as the employees of        Merial and Intervet\/Schering Plough.     <\/p>\n<p>       Sanofi-aventis remains strongly committed to its animal health        activities, which it will continue to develop under the Merial brand as        a growth platform of its diversified health business. Merial is one of        the world\u2019s leading innovation-driven animal healthcare companies        dedicated to research, development, manufacturing and commercialization        of veterinary pharmaceuticals and vaccines, that generated annual sales        of US $ 2.6 billion in 2010.     <\/p>\n<p>       Merck&#8217;s Intervet\/Schering-Plough is a global leader in the research,        development, manufacturing and sale of veterinary medicines and        generated sales of US $ 2.9 billion in 2010. Merck remains firmly        committed to animal health and intends to capitalize on        Intervet\/Schering-Plough&#8217;s broad and innovative portfolio going forward.     <\/p>\n<p>       As a result of termination, both Merial and Intervet\/Schering-Plough        will continue to operate independently. The termination of the agreement        is without penalty to either party and each party is responsible for its        own expenses.     <\/p>\n<p>       <b>About Merck<\/b>     <\/p>\n<p>       Today&#8217;s Merck is a global healthcare leader working to help the world be        well. Merck is known as MSD outside the United States and Canada.        Through our prescription medicines, vaccines, biologic therapies, and        consumer care and animal health products, we work with customers and        operate in more than 140 countries to deliver innovative health        solutions. We also demonstrate our commitment to increasing access to        healthcare through far-reaching policies, programs and partnerships. For        more information, visit <a target=\"_blank\" href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.merck.com&amp;esheet=6655519&amp;lan=en-US&amp;anchor=www.merck.com&amp;index=1&amp;md5=80586c0fd33b79e7ef24625fdb468cc9\">www.merck.com<\/a>.     <\/p>\n<p>       <b>About sanofi-aventis<\/b>     <\/p>\n<p>       Sanofi-aventis, a leading global pharmaceutical company, discovers,        develops and distributes therapeutic solutions to improve the lives of        everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New        York (NYSE: SNY).     <\/p>\n<p>       <b>About Intervet\/Schering-Plough Animal Health<\/b>     <\/p>\n<p>       Intervet\/Schering-Plough Animal Health, based in Boxmeer, the        Netherlands, is focused on the research, development, manufacturing and        marketing of animal health products. The company offers customers one of        the broadest, most innovative animal health portfolios, including        products to prevent, treat and control disease in all major farm and        companion animal species as well as products for reproduction        management. Intervet\/Schering-Plough Animal Health; subsidiaries of        Merck &amp; Co. Inc., Whitehouse Station NJ, USA. For more information,        visit <a target=\"_blank\" href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.intervet.com&amp;esheet=6655519&amp;lan=en-US&amp;anchor=www.intervet.com&amp;index=2&amp;md5=c2d5753485272f0e235d9a0e926ebc57\">www.intervet.com<\/a>.     <\/p>\n<p>       <b>About Merial<\/b>     <\/p>\n<p>       Merial is a world-leading, innovation-driven animal health company,        providing a comprehensive range of products to enhance the health,        well-being and performance of a wide range of animals. Merial employs        approximately 5,600 people and operates in more than 150 countries        worldwide. Formed in 1997, Merial is a leading animal health company        that was a 50\/50 joint venture between Merck and sanofi-aventis and is        now a wholly-owned subsidiary of sanofi-aventis, after Sanofi-aventis        acquired Merck\u2019s interest in Merial for a cash consideration of $4        billion (US) in 2009. For more information, please see\u00a0<a target=\"_blank\" href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.merial.com%2F&amp;esheet=6655519&amp;lan=en-US&amp;anchor=www.merial.com&amp;index=3&amp;md5=3b30a14e91f123141d2e77979a7f17ad\">www.merial.com<\/a>.     <\/p>\n<p>       <b>Forward-Looking Statement by Merck<\/b>     <\/p>\n<p>       This news release includes \u201cforward-looking statements\u201d within the        meaning of the safe harbor provisions of the United States Private        Securities Litigation Reform Act of 1995. Such statements may include,        but are not limited to, statements about the benefits of the merger        between Merck and Schering-Plough, including future financial and        operating results, the combined company\u2019s plans, objectives,        expectations and intentions and other statements that are not historical        facts. Such statements are based upon the current beliefs and        expectations of Merck\u2019s management and are subject to significant risks        and uncertainties. Actual results may differ from those set forth in the        forward-looking statements.     <\/p>\n<p>       The following factors, among others, could cause actual results to        differ from those set forth in the forward-looking statements: the        possibility that the expected synergies from the merger of Merck and        Schering-Plough will not be realized, or will not be realized within the        expected time period; the impact of pharmaceutical industry regulation        and health care legislation; the risk that the businesses will not be        integrated successfully; disruption from the merger making it more        difficult to maintain business and operational relationships; Merck\u2019s        ability to accurately predict future market conditions; dependence on        the effectiveness of Merck\u2019s patents and other protections for        innovative products; the risk of new and changing regulation and health        policies in the U.S. and internationally and the exposure to litigation        and\/or regulatory actions.     <\/p>\n<p>       Merck undertakes no obligation to publicly update any forward-looking        statement, whether as a result of new information, future events or        otherwise. Additional factors that could cause results to differ        materially from those described in the forward-looking statements can be        found in Merck\u2019s 2010 Annual Report on Form 10-K and the company\u2019s other        filings with the Securities and Exchange Commission (SEC) available at        the SEC\u2019s Internet site (<a target=\"_blank\" href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=6655519&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=4&amp;md5=e3770c686a3160631571fb014b1ea07e\">www.sec.gov<\/a>).     <\/p>\n<p>       <b>Forward Looking Statements by sanofi-aventis<\/b>     <\/p>\n<p>       This press release contains forward-looking statements as defined in the        Private Securities Litigation Reform Act of 1995, as amended.        Forward-looking statements are statements that are not historical facts.        These statements include projections and estimates and their underlying        assumptions, statements regarding plans, objectives, intentions and        expectations with respect to future financial results, events,        operations, services, product development and potential, and statements        regarding future performance. Forward-looking statements are generally        identified by the words \u201cexpects\u201d, \u201canticipates\u201d, \u201cbelieves\u201d, \u201cintends\u201d,        \u201cestimates\u201d, \u201cplans\u201d and similar expressions. Although sanofi-aventis\u2019        management believes that the expectations reflected in such        forward-looking statements are reasonable, investors are cautioned that        forward-looking information and statements are subject to various risks        and uncertainties, many of which are difficult to predict and generally        beyond the control of sanofi-aventis, that could cause actual results        and developments to differ materially from those expressed in, or        implied or projected by, the forward-looking information and statements.        These risks and uncertainties include among other things, the        uncertainties inherent in research and development, future clinical data        and analysis, including post marketing, decisions by regulatory        authorities, such as the FDA or the EMA, regarding whether and when to        approve any drug, device or biological application that may be filed for        any such product candidates as well as their decisions regarding        labelling and other matters that could affect the availability or        commercial potential of such products candidates, the absence of        guarantee that the products candidates if approved will be commercially        successful, the future approval and commercial success of therapeutic        alternatives, the Group\u2019s ability to benefit from external growth        opportunities as well as those discussed or identified in the public        filings with the SEC and the AMF made by sanofi-aventis, including those        listed under \u201cRisk Factors\u201d and \u201cCautionary Statement Regarding        Forward-Looking Statements\u201d in sanofi-aventis\u2019 annual report on Form        20-F for the year ended December 31, 2010. Other than as required by        applicable law, sanofi-aventis does not undertake any obligation to        update or revise any forward-looking information or statements.     <\/p>\n<p><p>       Merck<br \/>Media:<br \/>David Caouette, +1 (908) 423-3461<br \/>Steven        Campanini, +1 (908) 423-4291<br \/>or<br \/>Investors:<br \/>Joe        Romanelli, +1 (908) 423-5088<br \/>Carol Ferguson, +1 (908) 423-4465<br \/>or<br \/>sanofi        aventis<br \/>Media:<br \/>Jean-Marc Podvin, +33 1 53 77 42 23<br \/>or<br \/>Investors:<br \/>Sebastien        Martel, +33 1 53 77 45 45     <\/p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE: MRK) and sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today the mutual termination of their agreement to form a new animal health joint venture by combining Merial, the animal health business of sanofi-aventis, with Intervet\/Schering-Plough, Merck&#8217;s animal health unit. As a result, each party will keep its current, separate animal health assets and businesses. Since the initial announcement about the intended combination on March 9, 2010, both companies have worked diligently to create the proposed animal health joint venture, including submitting requests for the required antitrust reviews. The companies are discontinuing their agreement primarily because of the increasing complexity of implementing the proposed transaction, both in terms of the nature and extent of the anticipated divestitures and the length of time necessary for the worldwide regulatory review process. Merck and sanofi-aventis mutually determined that ending their plan is in the best<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,289],"class_list":["post-742134","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck and sanofi-aventis to Maintain Separate Businesses in Animal Health - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-sanofi-aventis-to-maintain-separate-businesses-in-animal-health\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck and sanofi-aventis to Maintain Separate Businesses in Animal Health - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE: MRK) and sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today the mutual termination of their agreement to form a new animal health joint venture by combining Merial, the animal health business of sanofi-aventis, with Intervet\/Schering-Plough, Merck&#039;s animal health unit. As a result, each party will keep its current, separate animal health assets and businesses. Since the initial announcement about the intended combination on March 9, 2010, both companies have worked diligently to create the proposed animal health joint venture, including submitting requests for the required antitrust reviews. The companies are discontinuing their agreement primarily because of the increasing complexity of implementing the proposed transaction, both in terms of the nature and extent of the anticipated divestitures and the length of time necessary for the worldwide regulatory review process. Merck and sanofi-aventis mutually determined that ending their plan is in the best\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-sanofi-aventis-to-maintain-separate-businesses-in-animal-health\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-10T17:01:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-sanofi-aventis-to-maintain-separate-businesses-in-animal-health\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-sanofi-aventis-to-maintain-separate-businesses-in-animal-health\\\/\",\"name\":\"Merck and sanofi-aventis to Maintain Separate Businesses in Animal Health - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2011-03-22T02:00:00+00:00\",\"dateModified\":\"2026-08-10T17:01:18+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-sanofi-aventis-to-maintain-separate-businesses-in-animal-health\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-sanofi-aventis-to-maintain-separate-businesses-in-animal-health\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-sanofi-aventis-to-maintain-separate-businesses-in-animal-health\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck and sanofi-aventis to Maintain Separate Businesses in Animal Health\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck and sanofi-aventis to Maintain Separate Businesses in Animal Health - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-sanofi-aventis-to-maintain-separate-businesses-in-animal-health\/","og_locale":"en_US","og_type":"article","og_title":"Merck and sanofi-aventis to Maintain Separate Businesses in Animal Health - Merck.com","og_description":"Merck (NYSE: MRK) and sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today the mutual termination of their agreement to form a new animal health joint venture by combining Merial, the animal health business of sanofi-aventis, with Intervet\/Schering-Plough, Merck's animal health unit. As a result, each party will keep its current, separate animal health assets and businesses. Since the initial announcement about the intended combination on March 9, 2010, both companies have worked diligently to create the proposed animal health joint venture, including submitting requests for the required antitrust reviews. The companies are discontinuing their agreement primarily because of the increasing complexity of implementing the proposed transaction, both in terms of the nature and extent of the anticipated divestitures and the length of time necessary for the worldwide regulatory review process. Merck and sanofi-aventis mutually determined that ending their plan is in the best","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-sanofi-aventis-to-maintain-separate-businesses-in-animal-health\/","og_site_name":"Merck.com","article_modified_time":"2026-08-10T17:01:18+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-sanofi-aventis-to-maintain-separate-businesses-in-animal-health\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-sanofi-aventis-to-maintain-separate-businesses-in-animal-health\/","name":"Merck and sanofi-aventis to Maintain Separate Businesses in Animal Health - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2011-03-22T02:00:00+00:00","dateModified":"2026-08-10T17:01:18+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-sanofi-aventis-to-maintain-separate-businesses-in-animal-health\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-sanofi-aventis-to-maintain-separate-businesses-in-animal-health\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-sanofi-aventis-to-maintain-separate-businesses-in-animal-health\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck and sanofi-aventis to Maintain Separate Businesses in Animal Health"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"1f5081ba-755d-4e86-9b9b-273b8d517061","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742134","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742134\/revisions"}],"predecessor-version":[{"id":3679270,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742134\/revisions\/3679270"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=742134"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=742134"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}